Blood -- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

Blood, Vol. 114, Issue 13, 2764-2773, September 24, 2009

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Blood Fandy et al. 114: 2764

Supplemental materials for: Fandy et al

Files in this Data Supplement:

Table S1. MSP and BSS Primer sets, base pair sizes, annealing temperatures and cycle number for each primer (PDF, 39.7 KB)
Table S2. Fold change in genes using supervised analysis (PDF, 28.1 KB)
Figure S1. Monitoring LINE-1 methylation in 5 patients during cycle one of treatment with 5AC and entinostat (JPG, 321 KB) -
(A) LINE-1 methylation in two clinical responders and three clinical non-responders before treatment (day 0) and after treatment (day 15 and 29). Data represent the mean ± SD for two replicates. NR indicates clinical non-responder and HI indicates hematological improvement. (B) LINE-1 methylation in two clinical responders (green line) and three clinical non-responders (red line) before treatment (day 0) and after treatment (day 15 and 29). Data represent the mean ± SD for two replicates.